Ohlmann Carsten-Henning, Gross-Langenhoff Marco
Department of Urology, Saarland University Medical Centre, Homburg, Germany.
Astellas Pharma GmbH, Munich, Germany.
Urol Int. 2018;100(1):66-71. doi: 10.1159/000479187. Epub 2017 Dec 1.
We evaluated the efficacy and tolerability of 3- and 6-month leuprorelin acetate (LA) depot formulations (Eligard®, Astellas Pharma GmbH) in patients with advanced prostate cancer treated in routine clinical practice in Germany.
Data was pooled from 2 prospective, open-label, non-interventional studies in which 1,906 patients were treated for 12 months with either the 3-month (n = 633) or 6-month (n = 1,273) LA formulation.
Median prostate-specific antigen levels in the pooled patient population declined from 12.0 ng/mL at baseline to 0.5 ng/mL after 12 months. Prostate-specific antigen reduction was achieved in treatment-naïve and pre-treated patients. Adverse events were documented in 8.8% of patients.
These pooled data from routine clinical practice in Germany indicate that LA 3- and 6-month depot injections can effectively reduce prostate-specific antigen levels in a broad patient population with advanced prostate cancer.
我们评估了3个月和6个月长效醋酸亮丙瑞林（LA）注射剂（Eligard®，安斯泰来制药有限公司）在德国常规临床实践中治疗晚期前列腺癌患者的疗效和耐受性。
数据来自2项前瞻性、开放标签、非干预性研究，其中1906例患者接受了3个月（n = 633）或6个月（n = 1273）LA注射剂治疗12个月。
汇总患者群体的前列腺特异性抗原（PSA）水平中位数从基线时的12.0 ng/mL降至12个月后的0.5 ng/mL。初治患者和经治患者均实现了PSA降低。8.8%的患者记录到不良事件。
来自德国常规临床实践的这些汇总数据表明，3个月和6个月的LA长效注射剂可有效降低广泛晚期前列腺癌患者群体的PSA水平。
